Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314801 | 0.92 | POLB (0.43) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1389099 | 0.77 | CYP1A2 (0.41) | SLC6A2 | |
| SCHEMBL27811490 | 0.72 | CYP1A2 (0.39) | SLC6A2 | |
| SCHEMBL6135690 | 0.70 | CYP3A4 (0.43) | POLBMEN1KMT2AALDH1A1SLC6A2 | |
| SCHEMBL30524953 | 0.70 | CETP (0.42) | MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL7228777 | 0.69 | DPP4 (0.42) | — | |
| SCHEMBL6679829 | 0.69 | CTSK (0.43) | ALDH1A1MAPK1 | |
| SCHEMBL8968952 | 0.68 | GAA (0.46) | — | |
| SCHEMBL11010892 | 0.68 | CYP3A4 (0.46) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL28139562 | 0.68 | CNR2 (0.37) | MEN1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-1585518-B9 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1585757-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1585518-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1585757-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7442793-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070173542-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2007-07-26 | — | — | US | disclosed |
| WO-2007067906-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067904-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| US-7166624-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-7019003-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| US-20060052423-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1585757-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | disclosed |
| WO-2004052919-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052423-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | POLB 2001/4885MEN1 2495/4885KMT2A 3860/4885 |
| US-20040087585-A1 | Peptide deformylase inhibitors | PDF, DPEP1, PEPD | POLB 1761/4885MEN1 2224/4885KMT2A 3452/4885 |
| US-20050222412-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | POLB 2001/4885MEN1 2495/4885KMT2A 3860/4885 |
| US-20070173542-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | POLB 2001/4885MEN1 2495/4885KMT2A 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.